Multimodal vaccination targeting the receptor binding domains of Clostridioides difficile toxins A and B with an attenuated Salmonella Typhimurium vector (YS1646) protects mice from lethal challenge
Microbiology Spectrum · 2024
DOI: 10.1128/spectrum.03109-22 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2024. Verfasst von Kaitlin Winter und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, McGill University, Montreal, Québec, Canada. Hauptthemen laut MEDLINE: Bacterial Toxins, Clostridioides difficile, Boron Compounds. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gouvernement du Canada | Canadian Institutes of Health Research (IRSC), Aviex Technologies LLC, Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (NSERC).
Abstract (Originalsprache)
Developing a vaccine against Clostridioides difficile is a key strategy to protect the elderly. Two candidate vaccines using a traditional approach of intramuscular (IM) delivery of recombinant antigens targeting C. difficile toxins A (TcdA) and B (TcdB) failed to meet their primary endpoints in large phase 3 trials. To elicit a mucosal response against C. difficile , we repurposed an attenuated strain of Salmonella Typhimurium (YS1646) to deliver the receptor binding domains (rbd) of TcdA and TcdB to the gut-associated lymphoid tissues, to elicit a mucosal response against C. difficile . In this study, YS1646 candidates with either rbdA or rbdB expression cassettes integrated into the bacterial chromosome at the att Tn 7 site were generated and used in a short-course multimodal vaccination strategy that combined oral delivery of the YS1646 candidate(s) on days 0, 2, and 4 and IM delivery of recombinant antigen(s) on day 0. Five weeks after vaccination, mice had high serum IgG titers and increased intestinal antigen-specific IgA titers. Multimodal vaccination increased the IgG avidity compared to the IM-only control. In the mesenteric lymph nodes, we observed increased IL-5 secretion and increased IgA + plasma cells. Oral vaccination skewed the IgG response toward IgG2c dominance (vs IgG1 dominance in the IM-only group). Both oral alone and multimodal vaccination against TcdA protected mice from lethal C. difficile challenge (100% survival vs 30% in controls). Given the established safety profile of YS1646, we hope to move this vaccine candidate forward into a phase I clinical trial. IMPORTANCE Clostridioides difficile remains a major public health threat, and new approaches are needed to develop an effective vaccine. To date, the industry has focused on intramuscular vaccination targeting the C. difficile toxins. Multiple disappointing results in phase III trials have largely confirmed that this may not be the best strategy. As C. difficile is a pathogen that remains in the intestine, we believe that targeting mucosal immune responses in the gut will be a more successful strategy. We have repurposed a highly attenuated Salmonella Typhimurium (YS1646), originally pursued as a cancer therapeutic, as a vaccine vector. Using a multimodal vaccination strategy (both recombinant protein delivered intramuscularly and YS1646 expressing antigen delivered orally), we elicited both systemic and local immune responses. Oral vaccination alone completely protected mice from lethal challenge. Given the established safety profile of YS1646, we hope to move these vaccine candidates forward into a phase I clinical trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, McGill University, Montreal, Québec, Canada.
- Research Institute of the McGill University Health Centre, Montreal, Québec, Canada.
- Institut National de Recherche Scientifique-Centre Armand-Frappier Santé Biotechnologie, Laval, Québec, Canada.
ORCID-Profile: Kaitlin Winter, Charles M Dozois, Brian J Ward
Förderung
- Gouvernement du Canada | Canadian Institutes of Health Research (IRSC)
- Aviex Technologies LLC
- Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (NSERC)
- FRQ | Fonds de Recherche du Québec - Santé (FRQS)
- Faculty of Medicine, McGill University (McGill Faculty of Medicine)
Zitieren
APA
Winter, K., Houle, S., Dozois, C. M., & Ward, B. J. (2024). Multimodal vaccination targeting the receptor binding domains of Clostridioides difficile toxins A and B with an attenuated Salmonella Typhimurium vector (YS1646) protects mice from lethal challenge. Microbiology Spectrum. https://doi.org/10.1128/spectrum.03109-22
Vancouver
Winter K, Houle S, Dozois CM, Ward BJ. Multimodal vaccination targeting the receptor binding domains of Clostridioides difficile toxins A and B with an attenuated Salmonella Typhimurium vector (YS1646) protects mice from lethal challenge. Microbiology Spectrum. 2024. doi:10.1128/spectrum.03109-22
BibTeX
@article{Winter2024,
author = {Winter, Kaitlin and Houle, Sébastien and Dozois, Charles M and Ward, Brian J},
title = {Multimodal vaccination targeting the receptor binding domains of Clostridioides difficile toxins A and B with an attenuated Salmonella Typhimurium vector (YS1646) protects mice from lethal challenge},
journal = {Microbiology Spectrum},
year = {2024},
doi = {10.1128/spectrum.03109-22}
}
EUVIMED